Arrowhead Pharmaceuticals Aktie
WKN DE: A2AGYB / ISIN: US04280A1007
10.03.2025 13:22:35
|
Arrowhead Pharma Reports Positive Topline Data From Phase 1/2 Study Of ARO-C3
(RTTNews) - Arrowhead Pharmaceuticals, Inc. (ARWR) Monday announced positive topline results from Part 2 of a Phase 1/2 study of ARO-C3 in patients with IgA nephropathy (IgAN).
ARO-C3 is designed to reduce hepatocyte production of complement component 3 (C3) as a potential treatment for various complement mediated renal diseases.
In Part 2 of the Phase 1/2 study, adult patients with C3 Glomerulopathy (C3G) and IgA Nephropathy (IgAN) received 3 doses of ARO-C3. Maximum mean reduction in C3 of 89 percent and mean sustained reduction of greater than 87 percent through week 24 in patients treated with ARO-C3 were observed. Mean reduction in spot urine protein-to-creatinine ratio (UPCR) of 41 was achieved by week 24.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Arrowhead Pharmaceuticals Incmehr Nachrichten
06.08.25 |
Ausblick: Arrowhead Pharmaceuticals präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net) |
Analysen zu Arrowhead Pharmaceuticals Incmehr Analysen
Aktien in diesem Artikel
Arrowhead Pharmaceuticals Inc | 30,52 | 3,21% |
|